Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:57:15.985Z.
Calculation as of: 2026-10-06T19:57:15.985Z.
Quote observation: 2026-10-06T19:55:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$138.03M
Price/OCF Ratio
99.23
TTM Avg
456.46
3Y Avg
456.46
5Y Avg
456.46
Market Cap
$139.50M
Price/OCF Ratio
N/A
TTM Avg
64.59
3Y Avg
64.59
5Y Avg
39.56
Market Cap
$136.89M
Price/OCF Ratio
N/A
TTM Avg
66.43
3Y Avg
66.43
5Y Avg
66.43
Market Cap
$144.06M
Price/OCF Ratio
1.14
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $138.49M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.03M | 99.23 | 456.46 | 456.46 | 456.46 |
| Sutro Biopharma, Inc. (STRO)vs › | $139.50M | N/A | 64.59 | 64.59 | 39.56 |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.89M | N/A | 66.43 | 66.43 | 66.43 |
| Atrium Therapeutics, Inc. (RNA)vs › | $135.73M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $142.10M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.21M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 1.14 | 4.90 | 4.90 | 4.90 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $144.66M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
